Contents9 sections
Cardiogen is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Arg (AEDR) and a molecular weight of 489.5 g/mol. Developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues, the Cardiogen peptide belongs to the class of short-chain bioregulator peptides designed to influence tissue-specific gene expression.
Unlike conventional peptides that bind cell-surface receptors, bioregulators in this class are small enough to enter cells and interact directly with DNA in the nucleus. Research on short bioregulatory peptides suggests they bind promoter regions of specific genes, modulating which genes are expressed. In this compound’s case, the target tissues are cardiac muscle cells (cardiomyocytes) and vascular endothelium.
The compound is not approved by the FDA or equivalent regulatory bodies for therapeutic use. It is available as a research peptide.
Key Takeaways
- Cardiogen is a tetrapeptide (AEDR) bioregulator that targets cardiac tissue gene expression.
- It was developed by Vladimir Khavinson at the St. Petersburg Institute as part of decades-long bioregulator research.
- It supports cardiac tissue repair, fibroblast regulation, and vascular function.
- Standard dosage: 10-20 mg subcutaneously every 3-7 days for 2-4 week cycles.
- It stacks with other bioregulators (Vilon, Vesugen) and recovery peptides (TB-500, BPC-157).
What Is Cardiogen?
Origin and Classification
The compound was developed through bioregulator research that began in the 1960s at the St. Petersburg Institute of Bioregulation and Gerontology. Vladimir Khavinson’s work established that short peptide sequences — typically 2-4 amino acids — could regulate specific organ functions by interacting with DNA at the gene expression level.
The Cardiogen bioregulator falls into the category of Khavinson peptides, named after the scientist who pioneered this research. Other peptides in this class include Vilon (immune system), Vesugen (vascular system), Epithalon (pineal gland/anti-aging), and Thymogen (thymus/immune function). Each targets specific tissue types through direct interaction with promoter regions of tissue-relevant genes.
Mechanism of Action
The proposed mechanism of action distinguishes this bioregulator from larger peptides and conventional supplements:
- Due to its small molecular weight (489.5 g/mol), the compound crosses cell membranes easily
- It enters the cell nucleus and binds to promoter regions on DNA that control heart-related gene expression
- This binding modulates which genes are activated or suppressed in cardiac cells
- The downstream effects include changes in protein synthesis that support tissue repair and function
This gene-expression mechanism means that the effects are not immediate like a stimulant or hormone — they develop gradually over the course of a treatment cycle and may persist beyond the dosing period as the altered gene expression patterns continue to influence cellular behavior.
Cardiogen Benefits
Cardiac Tissue Support
The primary Cardiogen benefits center on cardiac tissue maintenance and repair. Research suggests the peptide influences several processes relevant to heart health:
| Mechanism | Effect |
|---|---|
| Cardiomyocyte support | May promote growth and maintenance of heart muscle cells |
| Fibroblast regulation | May reduce excessive fibroblast activity that leads to cardiac scarring |
| p53 modulation | May lower p53 protein levels, reducing unnecessary cell death in cardiac tissue |
| Collagen organization | May support healthier collagen structure in heart tissue |
The fibroblast regulation aspect is particularly relevant for athletes and bodybuilders who subject their cardiovascular system to sustained high-intensity training. Excessive fibroblast activity in the heart can lead to fibrotic tissue (scarring) that reduces cardiac elasticity and function over time.
Vascular Function
The compound may support broader cardiovascular function beyond the heart muscle itself:
- Improved endothelial function in small blood vessels (microcirculation)
- Reduced oxidative stress in cardiac and vascular tissue
- Support for calcium homeostasis, which is essential for normal cardiac rhythm
- Enhanced tissue oxygenation through improved cardiac output
These vascular effects complement the direct cardiac tissue benefits, potentially improving overall cardiovascular performance and recovery capacity. Healthy microcirculation is particularly relevant for athletes, as improved blood flow to working muscles enhances nutrient delivery and waste removal during and after training. The combination of stronger cardiac output and better peripheral blood flow creates a more efficient cardiovascular system overall.
Recovery Applications
For individuals engaged in high-demand training, the therapeutic benefits may extend to cardiovascular recovery. Intense training programs and the use of stimulants or performance-enhancing compounds place additional strain on the heart and vascular system. The peptide’s tissue-repair mechanisms may help the cardiovascular system recover from this accumulated stress.
This recovery application is particularly relevant in the context of post-cycle therapy (PCT). Athletes transitioning off performance-enhancing compounds often experience a period of cardiovascular vulnerability as the body readjusts to endogenous hormone levels. Stacking a cardiac bioregulator during this transition may provide additional support for cardiovascular recovery alongside the standard hormonal recovery protocols.
Autonomic Nervous System Support
Research suggests the Cardiogen bioregulator may influence the autonomic nervous system’s regulation of cardiac function. Heart rate variability (HRV) — the variation in time between consecutive heartbeats — is a well-established marker of cardiovascular health and autonomic balance. Compounds that support HRV improvement are associated with better stress resilience, improved recovery capacity, and reduced risk of cardiac events.
By supporting the balance between sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) input to the heart, the peptide may help athletes maintain healthier cardiovascular adaptation to training stress. Monitoring HRV during a Cardiogen cycle provides objective data on whether the compound is producing measurable cardiovascular improvements for a given individual.
Cardiogen Dosage and Administration
Dosing Protocol
| Parameter | Recommendation |
|---|---|
| Cardiogen dosage | 10-20 mg per administration |
| Frequency | Every 3-7 days (subcutaneous) |
| Cycle length | 2-4 weeks |
| Off period | Equal to cycle length (2-4 weeks) |
| Administration route | Subcutaneous injection (preferred) |
The dosing protocol reflects the bioregulator’s gene-expression mechanism. Because the effects develop through altered gene activity rather than direct receptor stimulation, less frequent dosing is required compared to peptides that act through cell-surface receptors.
Injectable vs Oral
| Form | Bioavailability | Considerations |
|---|---|---|
| Subcutaneous injection | Highest | Preferred route; consistent absorption |
| Oral capsules | Lower | Peptide degradation in GI tract; higher doses needed |
As with most peptides, injectable administration delivers significantly more active compound to the bloodstream and produces more consistent therapeutic levels. Oral forms are available but require higher doses to compensate for gastrointestinal degradation, which increases cost without necessarily matching the effectiveness of injectable peptide protocols.
Stacking Protocols
The peptide integrates naturally into broader bioregulator and recovery peptide protocols due to its tissue-specific mechanism and lack of hormonal activity.
Bioregulator Combinations
| Stack | Target |
|---|---|
| Cardiogen + Vilon | Cardiac tissue + immune system support |
| Cardiogen + Vesugen | Cardiac tissue + vascular health (comprehensive cardiovascular) |
| Cardiogen + Thymogen | Cardiac recovery + immune reset (relevant for post-cycle therapy) |
Recovery Peptide Combinations
| Stack | Application |
|---|---|
| Cardiogen + BPC-157 | Cardiac support + systemic tissue repair (gut, soft tissue) |
| Cardiogen + TB-500 | Cardiac support + broad tissue regeneration and angiogenesis |
The compound does not interact with hormonal pathways, meaning it can be combined with recovery peptides, other bioregulators, or used alongside post-cycle therapy protocols without creating hormonal interference.
Safety and Side Effects
Reported Side Effects
The available clinical data and user reports suggest a mild side effect profile:
| Side Effect | Frequency | Notes |
|---|---|---|
| Mild fatigue | Uncommon | Transient; typically resolves within days |
| Injection site reaction | Uncommon | Minor redness or irritation |
| Temporary blood pressure fluctuation | Rare | Monitor if pre-existing BP concerns |
No significant drug interactions have been documented in the published literature. The peptide’s mechanism of action — influencing gene expression rather than directly modulating hormones or neurotransmitters — limits the scope of potential adverse interactions.
Limitations of the Evidence
The primary safety caveat is the limited scope of human clinical data. Most research on this compound has been conducted at the St. Petersburg Institute, and large-scale Western clinical trials have not been performed. The long-term safety profile of repeated bioregulator use is not well-characterized, and the gene-expression mechanism means that potential long-term effects are harder to predict than those of compounds acting through reversible receptor binding.
Users should monitor cardiovascular markers (resting heart rate, blood pressure, heart rate variability) during and after cycles to track individual response.
The Bottom Line
Cardiogen directly influences DNA promoter regions in heart cells and is fundamentally different from peptides that work through cell-surface receptors or hormonal pathways.
- For individuals seeking targeted cardiovascular support, the Cardiogen peptide offers a compelling mechanism with a favorable safety profile based on available data.
- As Western interest in bioregulator peptides continues to grow, additional clinical data will help clarify the compound’s full therapeutic potential and long-term safety profile.
Frequently Asked Questions
Disclaimer
Please read carefully
The information on this site is for educational and informational purposes only, and is not medical advice. Always consult a qualified healthcare professional before using any supplement or medication, or making changes to your health, fitness, or nutrition routine.
Not medical advice
Content here is not a substitute for professional medical advice.
Consult your doctor
Talk to your doctor before starting any supplement or new routine.
Use at your own risk
We are not responsible for adverse effects from acting on this.
Do your research
Make informed decisions about your own health.
No guarantees
Individual results vary. No claims about outcomes.
Important — Never disregard professional medical advice or delay seeking it because of something you read here. If you think you may have a medical emergency, call your doctor or your local emergency number right away.
